Amplius Wealth Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Amplius Wealth Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	335
2021 Q4	$0	Buy	+1	New	+$47	﹤0.01%	948

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Amplius Wealth Advisors's CYCN Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 1 share.

Amplius Wealth Advisors first reported a position in CYCN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

Amplius Wealth Advisors reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
Amplius Wealth Advisors sold 1 Cyclerion Therapeutics share in Q1 2022.
Amplius Wealth Advisors first reported a position in Cyclerion Therapeutics in Q4 2021 and held it in 1 quarter.
Amplius Wealth Advisors's Cyclerion Therapeutics position peaked at $0 in Q4 2021.
50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.